Get the Stockscreener App
1.25
14.64%
-0.15
Renovorx Inc stock is traded at $1.25, with a volume of 1.04M.
It is down -14.64% in the last 24 hours and up +38.10% over the past month.
RenovoRx Inc is a clinical-stage biopharmaceutical company developing proprietary targeted combination therapies for high unmet medical needs with a goal to improve therapeutic outcomes for cancer patients undergoing treatment. RenovoRx's patented Trans-Arterial Micro-Perfusion therapy platform is designed for targeted therapeutic delivery across the arterial wall near the tumor site (known as intra-arterial, or IA delivery) to bathe the target tumor, while potentially minimizing a therapy's toxicities versus systemic intravenous therapy.
See More
Previous Close:
$1.40
Open:
$1.415
24h Volume:
1.04M
Relative Volume:
3.30
Market Cap:
$55.51M
Revenue:
$1.49M
Net Income/Loss:
$-12.27M
P/E Ratio:
-3.7696
EPS:
-0.3316
Net Cash Flow:
$-11.30M
1W Performance:
+3.02%
1M Performance:
+38.10%
6M Performance:
+21.94%
1Y Performance:
+25.07%
1-Day Range:
$1.1799
$1.505
1-Week Range:
$1.10
$1.505
52-Week Range:
$0.7006
$1.505
Renovorx Inc Stock (RNXT) Company Profile
Name
Renovorx Inc
Sector
Industry
Phone
408-800-2649
Address
2570 W. EL CAMINO REAL, STE. 320,, MOUNTAIN VIEW
Compare RNXT vs VRTX, REGN, ARGX, RVMD, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RNXT
Renovorx Inc
|
1.23 | 63.18M | 1.49M | -12.27M | -11.30M | -0.3316 |
VRTX
Vertex Pharmaceuticals Inc
|
515.49 | 128.19B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
805.31 | 82.72B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
993.60 | 53.26B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
215.34 | 43.66B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
362.60 | 39.31B | 5.76B | 514.49M | 1.10B | 4.4813 |
Renovorx Inc Stock (RNXT) Latest News
RenovoRx Eyes 2027 TIGeR-PaC Readout as RenovoCath Expands to 21 Centers - sharewise.com
What is HC Wainwright's Forecast for RenovoRx Q3 Earnings? - MarketBeat
RenovoRx (NASDAQ:RNXT) Upgraded to "Hold" at Wall Street Zen - MarketBeat
Renovorx Stock Price Forecast. Should You Buy RNXT? - StockInvest.us
H.C. Wainwright Maintains RenovoRx(RNXT.US) With Buy Rating, Maintains Target Price $3 - Moomoo
RenovoRx Inc (NASDAQ: RNXT) Stock Price, News & Analysis - kalkine.ca
RenovoRx earnings beat by $0.02, revenue topped estimates - Investing.com Nigeria
RenovoRx Inc (RNXT) (Q2 2026) Earnings Call Highlights: Record Revenue and Strategic Expansion ... - Yahoo Finance
RenovoRx, Inc. Q2 2026 Earnings Call Summary - Yahoo Finance
RenovoRx Q2 Earnings Call Highlights - MarketBeat
RenovoRx (RNXT) Q2 2026 Earnings Call Transcript - AOL.com
RenovoRx Q2 revenue surges 115% YoY to $909,000; raises FY26 guidance - scanx.trade
RenovoRx raises FY26 sales guidance to $3.75M-$4.25M vs $3.2M est - scanx.trade
Earnings call transcript: RenovoRx posts Q2 2026 beat, lifts guidance By Investing.com - Investing.com Canada
RenovoRx Inc reports results for the quarter ended June 30Earnings Summary - TradingView
RenovoRx, Inc. (RNXT) Reports Q2 Loss, Beats Revenue Estimates - Yahoo Finance
RenovoRx Reports Record Second Quarter 2026 Results, Driven by Accelerating Commercial Adoption and 61% Sequential Quarterly Revenue Growth - Investing News Network
RenovoRx (NASDAQ:RNXT) Posts Earnings Results, Beats Estimates By $0.02 EPS - MarketBeat
Earnings call transcript: RenovoRx posts Q2 2026 beat, lifts guidance - Investing.com
RenovoRx, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
Renovorx, Inc. Increases Earnings Guidance for Full Year 2026 - marketscreener.com
RenovoRx Inc (RNXT) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
RenovoRx Achieves Major Milestone with Full Enrollment in Phase III TIGeR-PaC Trial for Locally Advanced Pancreatic Cancer - Investing News Network
RenovoRx completes enrollment in phase III pancreatic cancer trial - Investing.com
RenovoRx Inc (RNXT) Q2 2026: Everything You Need To Know Ahead Of Earnings - Yahoo Finance
Renovorx Achieves Major Milestone With Full Enrollment In Phase Iii Tiger-Pac Trial For Locally Advanced Pancreatic Cancer - TradingView
RenovoRx Inc (RNXT) Q2 2026: Everything You Need To Know Ahead O - GuruFocus
RenovoRx pancreatic cancer trial closes enrollment; 78 deaths occurred - Stock Titan
EXCLUSIVE: Renovorx Advances Its Targeted Pancreatic Cancer Therapy, Pivotal Data Expected in 2027 - Benzinga
RenovoRx Inc expected to post a loss of 7 cents a shareEarnings Preview - TradingView
RenovoRx (RNXT) Climbs 3.12% to $1.16 as Oncology Pipeline Keeps Micro-Cap in FocusNarrow Range Breakout - dars.gov.et
RenovoRx reports RenovoCath’s first clinical use in sarcoma - Medical Device Network
RenovoRx Inc (RNXT) Stock News Today - TradingKey
RenovoRx Announces First Commercial Clinical Use of RenovoCath in Sarcoma Patient Treatment, Marking Expansion of Targeted Drug-Delivery Device to Other Solid Tumors - marketscreener.com
Earnings Preview: RenovoRx to Report Financial Results Post-market on August 12 - Moomoo
RenovoRx’s RenovoCath used in sarcoma treatment for first time By Investing.com - Investing.com Nigeria
RenovoRx’s RenovoCath used in sarcoma treatment for first time - Investing.com
RenovoRx Announces First Commercial Clinical Use of RenovoCath® in Sarcoma Patient Treatment, Marking Expansion of Targeted Drug-Delivery Device to Other Solid Tumors - The Manila Times
A Sarcoma Patient Is Receiving Local Chemotherapy via RenovoCath - Stock Titan
RenovoRx Announces First Commercial Clinical Use Of RenovoCath In Sarcoma Patient Treatment - marketscreener.com
RenovoRx (RNXT) Gains 2.4% to $1.06: Micro-Cap Biotech Presses Against ResistanceMA Crossover - dars.gov.et
RenovoRx Highlights TAMP Platform in Upcoming Oncology Webinar - TipRanks
RenovoRx to Present TAMP Platform, TIGeR-PaC Trial Update at JonesTrading Webinar Aug 13 - TradingView
RenovoRx, Inc. (NASDAQ:RNXT): Are Analysts Optimistic? - webull.com
RenovoRx to Highlight TAMP™ Platform at JonesTrading Virtual Key Opinion Leader Webinar on the Evolving Pancreatic Cancer Landscape, August 13th - marketscreener.com
RenovoRx Webinar to Explore Local Chemotherapy for Pancreatic Cancer - Stock Titan
RenovoRx to highlight TAMP platform and record Q1 2026 sales at webinar - scanx.trade
RNXT|RenovoRx Inc|Price:1.040|Chg%:+0.082 - TradingKey
RenovoRx to Host Second Quarter 2026 Financial Results and Business Highlights Conference Call on August 12th at 4:30 p.m. ET - The Manila Times
Healthy You: United Regional’s cancer center marks its first year - AOL.com
RenovoRx Inc (RNXT) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Renovorx Inc Stock (RNXT) Financials Data
Revenue
Net Income
Cash Flow
EPS
Renovorx Inc Stock (RNXT) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Agah Ramtin | Chief Medical Officer |
Jan 21 '26 |
Buy |
1.00 |
10,000 |
9,975 |
798,460 |
| Agah Ramtin | Chief Medical Officer |
Dec 31 '25 |
Buy |
0.86 |
9,795 |
8,424 |
788,460 |
| Agah Ramtin | Chief Medical Officer |
Dec 30 '25 |
Buy |
0.83 |
205 |
169 |
778,665 |
| Bagai Shaun | Chief Executive Officer |
Dec 18 '25 |
Buy |
0.90 |
5,000 |
4,506 |
340,040 |
| Bagai Shaun | Chief Executive Officer |
Dec 17 '25 |
Buy |
0.85 |
5,000 |
4,262 |
335,040 |
| Agah Ramtin | Chief Medical Officer |
Dec 16 '25 |
Buy |
0.85 |
12,000 |
10,200 |
778,460 |
| Agah Ramtin | Chief Medical Officer |
Dec 05 '25 |
Buy |
0.96 |
10,000 |
9,600 |
766,460 |
| Agah Ramtin | Chief Medical Officer |
Nov 24 '25 |
Buy |
0.80 |
12,000 |
9,600 |
756,460 |
| Agah Ramtin | Chief Medical Officer |
Nov 21 '25 |
Buy |
0.80 |
10,000 |
8,000 |
744,460 |
| Bagai Shaun | Chief Executive Officer |
Aug 22 '25 |
Buy |
0.95 |
5,000 |
4,748 |
325,040 |
2.24%
1.78%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):